Debabrata Banerjee

Summary

Affiliation: New Jersey
Country: USA

Publications

  1. ncbi Identification of amino acids required for the functional up-regulation of human dihydrofolate reductase protein in response to antifolate Treatment
    Nancy Skacel
    Weill Cornell Graduate School of Medical Sciences, New York, New York, USA
    J Biol Chem 280:22721-31. 2005
  2. pmc Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier
    Rui Yang
    Department of Pediatrics and Molecular Pharmacology R, Y, R, G, The Albert Einstein College of Medicine, The Children s Hospital at Montefiore, Bronx, NY 10461, USA
    BMC Cancer 8:124. 2008
  3. ncbi Myeloprotection with drug-resistance genes
    Debabrata Banerjee
    Molecular Pharmacology and Experimental Therapeutics Program, Sloan Kettering Institute for Cancer Research, New York, USA
    Lancet Oncol 3:154-8. 2002
  4. ncbi Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase
    Debabrata Banerjee
    Program of Molecular Pharmacology and Experimental Therapeutics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Biochim Biophys Acta 1587:164-73. 2002
  5. ncbi EORTC-PAMM Group--24th Winter Meeting. 5-8 February 2003, Florence, Italy
    Debabrata Banerjee
    Cancer Institute of New Jersey, Room 3035, 195 Little Albany Street, New Brunswick, NJ 08901, USA
    IDrugs 6:290-3. 2003
  6. ncbi Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene
    Gina M Capiaux
    Graduate School of Medical Sciences, Cornell University, New York, NY 10021, USA
    Cancer Gene Ther 11:767-73. 2004
  7. pmc Translational modulation of proteins expressed from bicistronic vectors
    Prasun J Mishra
    Department of Pharmacology, Robert Wood Johnson Medical School, Cancer Institute of New Jersey, USA
    Mol Imaging 8:305-18. 2009
  8. ncbi Imaging of dihydrofolate reductase fusion gene expression in xenografts of human liver metastases of colorectal cancer in living rats
    Philipp Mayer-Kuckuk
    Molecular Pharmacology and Therapeutics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur J Nucl Med Mol Imaging 30:1281-91. 2003
  9. ncbi Molecular imaging reveals skeletal engraftment sites of transplanted bone marrow cells
    Philipp Mayer-Kuckuk
    In Vivo Cellular Molecular Imaging Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cell Transplant 15:75-82. 2006
  10. ncbi Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil
    Gina M Capiaux
    Graduate School of Medical Sciences, Cornell University, New York, NY 10021, USA
    Hum Gene Ther 14:435-46. 2003

Collaborators

Detail Information

Publications50

  1. ncbi Identification of amino acids required for the functional up-regulation of human dihydrofolate reductase protein in response to antifolate Treatment
    Nancy Skacel
    Weill Cornell Graduate School of Medical Sciences, New York, New York, USA
    J Biol Chem 280:22721-31. 2005
    ..The mutants that are not up-regulated by methotrexate are unable to bind their cognate mRNA...
  2. pmc Quantitative correlation between promoter methylation and messenger RNA levels of the reduced folate carrier
    Rui Yang
    Department of Pediatrics and Molecular Pharmacology R, Y, R, G, The Albert Einstein College of Medicine, The Children s Hospital at Montefiore, Bronx, NY 10461, USA
    BMC Cancer 8:124. 2008
    ..Heavy promoter methylation was previously identified as a basis for the complete silencing of RFC in MDA-MB-231 breast cancer cells, its role and prevalence in RFC transcription regulation are, however, not widely studied...
  3. ncbi Myeloprotection with drug-resistance genes
    Debabrata Banerjee
    Molecular Pharmacology and Experimental Therapeutics Program, Sloan Kettering Institute for Cancer Research, New York, USA
    Lancet Oncol 3:154-8. 2002
    ..Clinical trials, which have established that the approach is safe, are now being designed to address more therapeutically relevant issues...
  4. ncbi Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase
    Debabrata Banerjee
    Program of Molecular Pharmacology and Experimental Therapeutics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Biochim Biophys Acta 1587:164-73. 2002
    ....
  5. ncbi EORTC-PAMM Group--24th Winter Meeting. 5-8 February 2003, Florence, Italy
    Debabrata Banerjee
    Cancer Institute of New Jersey, Room 3035, 195 Little Albany Street, New Brunswick, NJ 08901, USA
    IDrugs 6:290-3. 2003
  6. ncbi Protection of hematopoietic stem cells from pemetrexed toxicity by retroviral gene transfer with a mutant dihydrofolate reductase-mutant thymidylate synthase fusion gene
    Gina M Capiaux
    Graduate School of Medical Sciences, Cornell University, New York, NY 10021, USA
    Cancer Gene Ther 11:767-73. 2004
    ..Co-expression of mutant DHFR and TS enzymes has additive effects in conferring resistance to pemetrexed-induced toxicity. This construct may be useful for conferring myeloprotection to patients receiving this drug...
  7. pmc Translational modulation of proteins expressed from bicistronic vectors
    Prasun J Mishra
    Department of Pharmacology, Robert Wood Johnson Medical School, Cancer Institute of New Jersey, USA
    Mol Imaging 8:305-18. 2009
    ..To our knowledge, this is the first report demonstrating that levels of proteins in DHFR-based bicistronic constructs can be induced and modulated using MTX and rapamycin treatment...
  8. ncbi Imaging of dihydrofolate reductase fusion gene expression in xenografts of human liver metastases of colorectal cancer in living rats
    Philipp Mayer-Kuckuk
    Molecular Pharmacology and Therapeutics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Eur J Nucl Med Mol Imaging 30:1281-91. 2003
    ..It is concluded that the two examined nucleotide imaging methods are feasible techniques for monitoring of DHFR-HSV TK fusion protein expression in hepatic colorectal tumor tissue in living animals...
  9. ncbi Molecular imaging reveals skeletal engraftment sites of transplanted bone marrow cells
    Philipp Mayer-Kuckuk
    In Vivo Cellular Molecular Imaging Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cell Transplant 15:75-82. 2006
    ..Multiple, discrete BM cell engraftment sites were observed. Taken together, this multimodality approach may be useful for further in vivo characterization of various therapeutic cell types...
  10. ncbi Retroviral transduction of a mutant dihydrofolate reductase-thymidylate synthase fusion gene into murine marrow cells confers resistance to both methotrexate and 5-fluorouracil
    Gina M Capiaux
    Graduate School of Medical Sciences, Cornell University, New York, NY 10021, USA
    Hum Gene Ther 14:435-46. 2003
    ..As MTX and 5-FU are used in combination therapy for diseases such as breast and colon cancer, this fusion gene may be useful in the clinic to reduce myelosuppressive toxicity associated with this drug combination...
  11. pmc Species-specific differences in translational regulation of dihydrofolate reductase
    Yi Ching Hsieh
    Department of Medicine and Pharmacology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08903, USA
    Mol Pharmacol 76:723-33. 2009
    ..We also present evidence to suggest that the translational up-regulation of dihydrofolate reductase by methotrexate in tumor cells is an adaptive mechanism that decreases sensitivity to this drug...
  12. pmc Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
    Pravin J Mishra
    Department of Medicine, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08903, USA
    Cancer Res 68:4331-9. 2008
    ..To our knowledge, this is the first report showing that hMSCs become activated and resemble carcinoma-associated myofibroblasts on prolonged exposure to conditioned medium from MDAMB231 human breast cancer cells...
  13. doi Mesenchymal stem cells: flip side of the coin
    Pravin J Mishra
    Department of Medicine, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 8903, USA
    Cancer Res 69:1255-8. 2009
    ....
  14. ncbi Overexpression of E2F-1 in lung and liver metastases of human colon cancer is associated with gene amplification
    Marian Iwamoto
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer Biol Ther 3:395-9. 2004
    ..In as much as TS is transcriptionally regulated by E2F-1, these results provide an explanation for the high levels of TS mRNA noted in some tumor samples...
  15. doi Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium
    Hui Gao
    Department of Medicine, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA
    Stem Cells 27:857-65. 2009
    ..Taken together, our results provide insight into the molecular pathways responsible for MSC migration toward the tumor microenvironment and may provide the molecular basis for modifying MSCs for therapeutic purposes...
  16. pmc The isolation of novel mesenchymal stromal cell chemotactic factors from the conditioned medium of tumor cells
    Siang Yo Lin
    Department of Pharmacology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903, USA
    Exp Cell Res 314:3107-17. 2008
    ..Two proteins, cyclophilin B and hepatoma-derived growth factor were then further characterized and shown to promote MSC chemotaxis...
  17. pmc Imaging colon cancer response following treatment with AZD1152: a preclinical analysis of [18F]fluoro-2-deoxyglucose and 3'-deoxy-3'-[18F]fluorothymidine imaging
    Maxim A Moroz
    Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 17:1099-110. 2011
    ..Additional studies assessed the endogenous and exogenous contributions of thymidine synthesis in the two cell lines...
  18. ncbi mRNA expression levels of E2F transcription factors correlate with dihydrofolate reductase, reduced folate carrier, and thymidylate synthase mRNA expression in osteosarcoma
    Rebecca Sowers
    Department of Pediatrics, Orthopaedic Surgery Service, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Cancer Ther 2:535-41. 2003
    ....
  19. ncbi MiRSNPs or MiR-polymorphisms, new players in microRNA mediated regulation of the cell: Introducing microRNA pharmacogenomics
    Prasun J Mishra
    Department of Pharmacology and Medicine, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Jersey, USA
    Cell Cycle 7:853-8. 2008
    ....
  20. pmc Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs
    Yi Ching Hsieh
    Departments of Pharmacology and Medicine, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA
    Mol Pharmacol 83:339-53. 2013
    ..We suggest that NAD kinase is a valid target for further inhibitor development for cancer treatment...
  21. ncbi High-resolution imaging of bone precursor cells within the intact bone marrow cavity of living mice
    Philipp Mayer-Kuckuk
    In Vivo Cellular Molecular Imaging Center, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Mol Ther 12:33-41. 2005
    ..In summary, we describe a versatile platform suitable for studying the biology of many bone marrow cell types in living bone...
  22. ncbi Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene
    Tulin Budak-Alpdogan
    Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
    Mol Ther 10:574-84. 2004
    ..05), suggesting that early treatment allowed for enrichment of transduced marrow progenitors. These results encourage clinical studies using this retroviral fusion gene construct...
  23. doi Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu
    Yanique Rattigan
    Department of Pharmacology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903, USA
    Exp Cell Res 316:3417-24. 2010
    ..Collectively, our data demonstrate that hypoxic tumor cells specifically recruit MSCs, which through activation of signaling and survival pathways facilitate tumor progression...
  24. ncbi E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents
    Angelo J Russo
    The Cancer Institute of New Jersey, Robert Wood Johnson School of Medicine, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08903, USA
    Cancer Res 66:7253-60. 2006
    ..These studies add support to recent reports that show E2F regulates genes involved in mitotic entry and exit and allow the suggestion that mitotic inhibitors may have selective effects in tumors that overexpress E2F-1...
  25. pmc Lactate is a mediator of metabolic cooperation between stromal carcinoma associated fibroblasts and glycolytic tumor cells in the tumor microenvironment
    Yanique I Rattigan
    Graduate School of Biomedical Sciences, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08901, USA
    Exp Cell Res 318:326-35. 2012
    ..To our knowledge this is the first in vitro model system demonstrating that hMSCs and CAFs can utilize lactate produced by tumor cells...
  26. ncbi Hematopoietic stem cell gene therapy with drug resistance genes: an update
    Tulin Budak-Alpdogan
    Department of Medicine, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, New Jersey 08903, USA
    Cancer Gene Ther 12:849-63. 2005
    ..In this review, we describe ongoing experimental approaches, observations from clinical trials, and safety concerns related to the drug resistance gene transfer...
  27. ncbi p14ARF expression increases dihydrofolate reductase degradation and paradoxically results in resistance to folate antagonists in cells with nonfunctional p53
    Pellegrino G Magro
    Joan and Sanford I Weill Graduate School of Medical Sciences of Cornell University, and Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Cancer Res 64:4338-45. 2004
    ..Depletion of thymidine in the medium reversed this resistance, indicating that p14(ARF) induction increases the reliance of these cells on thymidine salvage...
  28. ncbi Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time?
    Joseph R Bertino
    The Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA
    Clin Cancer Res 9:1235-9. 2003
  29. pmc A miR-24 microRNA binding-site polymorphism in dihydrofolate reductase gene leads to methotrexate resistance
    Prasun J Mishra
    Department of Pharmacology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903, USA
    Proc Natl Acad Sci U S A 104:13513-8. 2007
    ..We demonstrate that a naturally occurring miRSNP (a SNP located at or near a microRNA binding site in 3' UTR of the target gene or in a microRNA) is associated with enzyme overproduction and drug resistance...
  30. ncbi Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells
    Lata G Menon
    Department of Medicine, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey 08903, USA
    Stem Cells 25:520-8. 2007
    ..These results suggest that increased SDF-1 production by MSCs acts in an autocrine manner and is required for migratory responses to tumor cells...
  31. pmc A second target of benzamide riboside: dihydrofolate reductase
    Breton Roussel
    Department of Medicine, Biochemistry and Pharmacology, Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    Cancer Biol Ther 13:1290-8. 2012
    ..As consequence of the lack of NADPH, DHFR was shown to be destabilized. We suggest that, inhibition of NADK is a new approach to downregulate DHFR and to inhibit cell growth...
  32. pmc Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab
    Nora M Barboza
    Department of Medicine, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA
    Cancer Biol Ther 13:114-22. 2012
    ....
  33. ncbi Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer
    Mithat Gonen
    Departments of Epidemiology and Biostatistics, Medicine, Surgery, and Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 21:406-12. 2003
    ....
  34. doi Epigenetic reversal of acquired resistance to 5-fluorouracil treatment
    Rita Humeniuk
    Department of Medicine and Pharmacology, Robert Wood Johnson Medical School, The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, 195 Little Albany Street, New Brunswick, NJ 08903, USA
    Mol Cancer Ther 8:1045-54. 2009
    ....
  35. ncbi Fluoropyrimidine resistance in colon cancer
    Richard Gorlick
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Expert Rev Anticancer Ther 2:409-16. 2002
    ..Clinical trials that can potentially overcome the relevant mechanisms of resistance are described...
  36. ncbi Molecular therapies for colorectal cancer metastatic to the liver
    Philipp Mayer-Kuckuk
    Program of Molecular Pharmacology and Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Mol Ther 5:492-500. 2002
    ..Here we review molecular therapies for colorectal cancer metastatic to the liver...
  37. ncbi Role of reporter gene imaging in molecular and cellular biology
    Philipp Mayer-Kuckuk
    Department of Pharmacology, The Cancer Institute of New Jersey, UMDNJ, New Brunswick, NJ 08903, USA
    Biol Chem 385:353-61. 2004
    ..The review indicates that molecular imaging is likely to be useful in the translation of molecular biology to medicine and biotechnological applications...
  38. doi Protein kinase C zeta regulates interleukin-8-mediated stromal-derived factor-1 expression and migration of human mesenchymal stromal cells
    Sonia C Picinich
    Graduate School of Biomedical Sciences, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ, USA
    Exp Cell Res 316:593-602. 2010
    ..This signaling pathway provides insight into possible molecular targets for cancer therapy aimed at disrupting the interaction between components of the tumor microenvironment...
  39. doi Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance
    Rita Humeniuk
    The Graduate School of Biomedical Sciences, Department of Pharmacology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 08903, USA
    Mol Cancer Ther 8:1037-44. 2009
    ..Our findings provide new insights into the mechanisms of acquired resistance to 5-FU in colorectal cancer and implicate UMPK as an important mechanism of clinical resistance to pulse 5-FU treatment in some patients...
  40. pmc P53 regulates the migration of mesenchymal stromal cells in response to the tumor microenvironment through both CXCL12-dependent and -independent mechanisms
    Siang Yo Lin
    Department of Pediatrics, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903, USA
    Int J Oncol 43:1817-23. 2013
    ..Stromal p53 may influence other important aspects of tumor biology such as tumor growth and metastasis through mechanisms distinct from CXCL12. ..
  41. doi Activation and differentiation of mesenchymal stem cells
    Pravin J Mishra
    Department of Medicine and Pharmacology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, UMDNJ, New Brunswick, NJ, USA
    Methods Mol Biol 717:245-53. 2011
    ..Here, we show that keratinocyte-conditioned medium (KCM) induces differentiation of MSCs to resemble dermal myofibroblast-like cells using immunofluorescence techniques demonstrating punctate vinculin staining, and F-actin filaments...
  42. ncbi Tumor initiating cells
    Nitu Bansal
    Cancer Institute of New Jersey, RWJMS UMDNJ, 195 Little Albany Street, New Brunswick, NJ 08903, USA
    Curr Pharm Biotechnol 10:192-6. 2009
    ..Strategies that combine conventional therapies with newer approaches that target the TICs may be more effective in tumor cell kill are discussed...
  43. pmc Transformation of benign Barrett's epithelium by repeated acid and bile exposure over 65 weeks: a novel in vitro model
    Kiron M Das
    Department of Medicine, UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ, USA
    Int J Cancer 128:274-82. 2011
    ..We demonstrate a novel in vitro model of transformation of a benign Barrett's cell line following repeated exposure to A+B over the course of 65 weeks...
  44. pmc Cells exposed to antifolates show increased cellular levels of proteins fused to dihydrofolate reductase: a method to modulate gene expression
    Philipp Mayer-Kuckuk
    Molecular Pharmacology and Therapeutics Program, Department of Surgery, Nuclear Medicine Service, Radiochemistry Cyclotron, and Preparative Synthesis Chemistry Core Facilities, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 99:3400-5. 2002
    ..Drug-mediated elevation of cellular DHFR-fused proteins is a very useful method to modulate gene expression in vivo for imaging as well as therapeutic purposes...
  45. ncbi Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo
    Naoto Takahashi
    Program of Molecular Pharmacology and Therapeutics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer Res 62:6909-15. 2002
    ..These results suggest that the combination of ET-743 and paclitaxel should be assessed in clinical trials for the treatment of breast cancer...
  46. ncbi The therapeutic potential of mesenchymal stem cells. Cell- & tissue-based therapy
    Sonia C Picinich
    University of Medicine and Dentistry of New Jersey, Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA
    Expert Opin Biol Ther 7:965-73. 2007
    ..Here, the authors review recent work contributing to the knowledge of MSC biology and the advances in gene therapy and tissue regeneration using MSCs...
  47. doi Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy
    Pravin Mishra
    Department of Medicine and Pharmacology, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, USA
    J Leukoc Biol 89:31-9. 2011
    ..The overall findings suggest that chemokines stand at the crossroads of tumor-CAF interactions that lead to increased malignancy in many cancer diseases...
  48. ncbi The Raz mTaz of human mesenchymal stem cells
    Debabrata Banerjee
    Cancer Institute of New Jersey, University of Medicine and Dentistry Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA
    Stem Cells Dev 16:691-3. 2007
  49. ncbi Pharmacogenomics of microRNA: a miRSNP towards individualized therapy
    Joseph R Bertino
    Pharmacogenomics 8:1625-7. 2007
  50. ncbi Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer
    Kiranmayi Tadi
    Department of Microbiology and Immunology, New York Medical College, Valhalla, New York 10595, USA
    Cancer Biol Ther 6:1632-7. 2007
    ..These studies identify C-1748 as a novel acridine drug that has a high therapeutic index and low cytotoxicity on myelocytic cells with potential for clinical development...